Testosterone replacement therapy following the diagnosis of prostate cancer: Outcomes and utilization trends

Journal of Sexual Medicine

Volumn 11, Issue 4, 2014, Pages 1063-1070

  Kaplan, Alan L ^a   Trinh, Quoc Dien ^b   Sun, Maxine ^c   Carter, Stacey C ^a   Nguyen, Paul L ^b   Shih, Ya Chen Tina ^d   Marks, Leonard S ^a   Hu, Jim C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Androgen replacement; Late onset hypogonadism; Prostate cancer; Testosterone deficiency syndrome; Testosterone replacement therapy

Indexed keywords

TESTOSTERONE;

AGE; AGED; ANDROGEN THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURGERY; DISEASE SURVEILLANCE; EDUCATIONAL STATUS; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; WATCHFUL WAITING;

ANDROGEN REPLACEMENT; LATE-ONSET HYPOGONADISM; PROSTATE CANCER; TESTOSTERONE DEFICIENCY SYNDROME; TESTOSTERONE REPLACEMENT THERAPY;

AGED; ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SALVAGE THERAPY; TESTOSTERONE;

EID: 84897534342     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12429     Document Type: Article

References (31)

1. Khera M, Lipshultz LI. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am 2007;34:549-553.
2. Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potentials benefits, and risks of testosterone replacement therapy. Int J Endocrinol 2012;2012:625434.
3. Harman SM, Metter EJ, Tobin JD, etal. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab 2001;86:724-731.
4. Wu FC, Tajar A, Beynon JM, etal. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-135.
5. Tajar A, Huhtaniemi IT, O'Neill TW, etal. Characteristics of androgen deficiency in late-onset hypogonadism: Results from the European male aging study. J Clin Endocrinol Metab 2012;97:1508-1516.
6. Marks LS, Mazer NA, Mostaghel E, etal. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. JAMA 2006;296:2351-2361.
7. Morgentaler A. Testosterone and prostate cancer: What are the risks for middle-aged men? Urol Clin North Am 2011;38:119-124.
8. Wang C, Cunningham G, Dobs A, etal. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
9. Dorff TB, Vogelzang NJ. Use of testosterone replacement therapy in patients with prostate cancer. Curr Urol Rep 2011;12:223-228.
10. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006;50:935-939.
11. Huggins C, Hodges CV. Studies on prostate cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic cercinoma of the prostate. Cancer Res 1941;1:293-297.
12. Fowler JE, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372-375.
13. Potosky AL, Riley GF, Lubitz JD, etal. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-748.
14. Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER program of the National Cancer Institute. Cancer 1995;76:2343-2350.
15. Klabunde CN, Potosky AL, Legler JM, etal. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267.
16. Hu JC, Williams SB, O'Malley AJ, etal. Androgren-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol 2012;61:1119-1128.
17. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassifications on the propensity score. J Am Stat Assoc 1984;79:516-524.
18. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763.
19. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920-922.
20. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173:533-536.
21. Khera M, Grober ED, Najari B, etal. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009;6:1165-1170.
22. Pastuszak AW, Pearlman AM, Lai WS, etal. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013;190:639-644.
23. Sarosdy MF. Testosterone replacement for hyogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109:536-541.
24. Morgentaler A. Testosterone therapy in men with prostate cancer: Scientific and ethical considerations. J Urol 2013;189:S26-33.
25. Morgentaler A, Lipshultz LI, Bennett R, etal. Testosterone therapy in men with untreated prostate cancer. J Urol 2011;185:1256-1260.
26. Kaplan AL, Hu JC. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology 2013;82:321-326.
27. Araujo AB, O'Donnell AB, Brambilla DJ, etal. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 2004;89:5920-5926.
28. Khera M, Bhattacharya RK, Blick G, etal. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male 2012;15:14-21.
29. Khera M, Bhattacharya RK, Blick G, etal. Improved sexual function with testosterone replacement therapy in hypogonadal men: Real-world data from the Testim Registry in the US (TRiUS). J Sex Med 2011;8:3204-3213.
30. Trost LW, Hellstrom WJ. Testosterone deficiency, supplementation, and prostate cancer: Maintaining a balanced perspective. J Sex Med 2013;10:2879-2881.
31. Buvat J, Maggi M, Guay A, etal. Testosterone deficiency in men: Systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013;10:245-284.